Orthovisc has been available for 20 years, 3 months, and 9 days, as of May 14, 2024, since its initial FDA approval on February 5, 2004.
Understanding Orthovisc's Presence in the Market
Orthovisc, a brand of sodium hyaluronate, is a significant medical treatment used to alleviate knee pain caused by osteoarthritis. Its availability in the market commenced following its official clearance by the U.S. Food and Drug Administration (FDA).
Key Milestones in Orthovisc's History
The journey of Orthovisc into widespread clinical use began with its crucial FDA approval. This milestone marked the point when the treatment became accessible to patients seeking non-surgical options for managing their knee osteoarthritis symptoms.
| Date | Event |
|---|---|
| February 5, 2004 | FDA Approval for Orthovisc by Anika Therapeutics, Inc. for the treatment of osteoarthritis of the knee. |
Calculating Its Market Duration
To precisely determine the period Orthovisc has been available to patients, we calculate the time elapsed since its FDA approval date:
- Approval Date: February 5, 2004
- Calculation Date: May 14, 2024
Based on these dates, Orthovisc has been on the market for:
- Years: 20 years (from February 5, 2004, to February 5, 2024)
- Months: 3 months (from February 5, 2024, to May 5, 2024)
- Days: 9 days (from May 5, 2024, to May 14, 2024)
This consistent presence over more than two decades highlights its established role in the therapeutic landscape for knee osteoarthritis. For more detailed historical information regarding Orthovisc's development and approval, you can refer to its FDA approval history.
